Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will provide a corporate update and engage in one-on-one investor meetings. The presentation is scheduled for May 24, 2022, at 7:00 a.m. ET. Selecta is focused on developing tolerogenic therapies via its ImmTOR® platform to treat autoimmune diseases and enhance gene therapies. Investors can access a webcast of the presentation and archived materials on their official website.
- None.
- None.
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.
H.C. Wainwright Global Investment Conference
Format: Pre-recorded presentation and one-on-one investor meetings
Date: Tuesday, May 24, 2022
Time: Presentation available at 7:00 a.m. ET
Webcast: Click Here
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
When is Selecta Biosciences participating in the H.C. Wainwright Global Investment Conference?
What time is Selecta's presentation at the H.C. Wainwright Conference?
Where can I watch the Selecta Biosciences presentation?
What is Selecta Biosciences' focus in biotechnology?
What is the stock symbol for Selecta Biosciences?
